Merck MRK.DE
Merck KGaA is a German science and technology company with three sectors: Healthcare, Life Science, and Electronics. Merck KGaA shows solid financial health (ND/EBITDA 1.64) and a reasonable valuation with a forward P/E of 15.32, but earnings growth is negative (-24.70%) and quality (ROE 8.13%) is mediocre. The Bio-Techne acquisition is a key catalyst that could improve growth prospects.
Detailed metrics
Market and fundamental data as of the analysis date.
Full AI report
Generated automatically from the metrics, the macro context and the company's news.
Merck KGaA is a German science and technology company with three sectors: Healthcare, Life Science, and Electronics. Merck KGaA shows solid financial health (ND/EBITDA 1.64) and a reasonable valuation with a forward P/E of 15.32, but earnings growth is negative (-24.70%) and quality (ROE 8.13%) is mediocre. The Bio-Techne acquisition is a key catalyst that could improve growth prospects.
Score by category
| Category | Score |
|---|---|
| Financial health | 6.7 |
| Quality / Moat | 5.2 |
| Valuation | 5.7 |
| Growth | 3.2 |
| Dividend | 6.2 |
| Momentum | 6.0 |
| Risk & Context | 7.0 |
OVERALL SCORE: 5.6/10
Context and risks
Moderate regulatory risk in Germany and exposure to regulatory approval of the Bio-Techne acquisition, which is not yet closed. The pharmaceutical sector is under pricing pressure, a standard risk for the industry.
News considered in the analysis
- Bio-Techne (TECH) Shareholders Approve the Merck KGaA Takeover and Reject the Pay Package — La aprobación de los accionistas de Bio-Techne elimina un obstáculo clave para la adquisición, un paso material hacia la finalización del acuerdo.
- Merck KGaA (XTRA:MRK) Clears Key Acquisition Hurdle After Shareholder Approval — Confirma el avance en la adquisición de Bio-Techne, un movimiento estratégico que refuerza la cartera de Life Science.
- TwoStep Therapeutics raises $62.5m in funding to advance TS-104 — Noticia sobre una empresa externa sin impacto directo en los fundamentales de Merck KGaA.
- Merck KGaA shares rise 1.7% after HSBC upgrades stock to Buy — La mejora de recomendación de HSBC refleja una visión positiva, pero es una opinión de analista que ya está parcialmente en el precio.
- Merck KGaA (XTRA:MRK) Stock May Be Below Fair Value Despite Fresh Drug Pipeline Funding — El artículo sugiere que la acción está infravalorada, un sentimiento positivo que aún no se ha reflejado completamente en el precio.
Verdict: Hold, with attention to the progress of the Bio-Techne acquisition and the company's ability to reverse the earnings decline.
Main risk: The main risk is the integration and success of the Bio-Techne acquisition, which is crucial to drive future growth in an environment of currently declining earnings.
Other Healthcare companies
Neighbours in the sector ranking, to compare without going back to the index.
See all 1,000+ companies in the index →